<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176835</url>
  </required_header>
  <id_info>
    <org_study_id>00861</org_study_id>
    <nct_id>NCT04176835</nct_id>
  </id_info>
  <brief_title>Oxytocin and Social Decision Making in Schizophrenia</brief_title>
  <official_title>Neurobiological Effects of Oxytocin on Social Decision Making in Schizophrenia: A Pharmacological MRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health and Neuro Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Mental Health and Neuro Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      schizophrenia patients and healthy volunteers will be included. Subjects who meet the
      inclusion and exclusion criteria for the study will be recruited. After completion of
      clinical assessments and neuropsychological assessments, all subjects will undergo two fMRI
      scans. In one scan subjects will receive a single dose of intranasal oxytocin and in another
      scan, they will receive intranasal saline. The order of administration of oxytocin or saline
      will be counterbalanced so that they are not administered in the same order to all subjects.
      Subjects will be blind to the drug administered.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fMRI changes with oxytocin while performing ultimatum game and at rest</measure>
    <time_frame>90 minutes</time_frame>
    <description>Changes in brain activity and functional connectivity</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose intranasal oxytocin or intranasal placebo administered in counterbalanced order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single-dose intranasal oxytocin or intranasal placebo administered in counterbalanced order</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin nasal spray</intervention_name>
    <description>Single-dose oxytocin will be administered intranasally</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>oxytocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Schizophrenia group -

        Inclusion Criteria:

          1. Males between 18 and 45 years with at least 7 years of education

          2. The DSM-IV diagnosis of Schizophrenia or schizoaffective or schizophreniform disorder

          3. capacity to provide informed consent

        Exclusion Criteria:

          1. Current comorbid DSM-IV axis I diagnosis

          2. General impaired intellectual functioning

          3. history of alcohol or substance abuse or dependence in the last 12 months

          4. contraindication to Oxytocin like hypersensitivity, vascular disease, chronic
             nephritis, epilepsy, asthma

          5. past history of head injury resulting in loss of consciousness or neurosurgery

          6. concomitant severe medical conditions

          7. metal implants or paramagnetic objects within the body or claustrophobia which may
             interfere with the MRI.

        Healthy volunteers:

        Inclusion Criteria:

          1. Males between 18 and 45 years with at-least 7 years education

          2. Capacity to provide informed consent

          3. absence of past or present psychiatric illnesses including substance abuse/dependence

        Exclusion criteria:

          1. General impaired intellectual functioning

          2. contraindication to Oxytocin like hypersensitivity, vascular disease, chronic
             nephritis, epilepsy, asthma

          3. past history of head injury resulting in loss of consciousness or neurosurgery

          4. concomitant severe medical conditions

          5. metal implants or paramagnetic objects within the body or claustrophobia which may
             interfere with the MRI.

          6. Family history of schizophrenia or schizoaffective or schizophreniform disorder in a
             first-degree relative
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Mental Health and Neuro Sciences, India</investigator_affiliation>
    <investigator_full_name>Dr Naren P Rao</investigator_full_name>
    <investigator_title>Additional Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

